22 August 2021: Clinical Research
Association Between Blood Pressure Control and Arterial Stiffness in Middle-Aged and Elderly Chinese Patients with Hypertension
Geyue Qu ABCDEF* , Zhongying Zhang AEF , Hong Zhu BCDDOI: 10.12659/MSM.931414
Med Sci Monit 2021; 27:e931414
Table 1 Patient characteristics*.
| Variables | blood pressure control | P | Total | |
|---|---|---|---|---|
| Well-controlled BP** | Uncontrolled BP** | |||
| n | 169 | 143 | 312 | |
| Age, year | 69.6±12.0 | 66.7±13.1 | 0.048 | 68.3±12.6 |
| Male, n (%) | 99 (58.6) | 98 (68.5) | 0.069 | 197 (63.1) |
| Systolic BP, mmHg | 123.6±9.7 | 148.4±14.5 | 0.000 | 135.0±17.3 |
| Diastolic BP, mmHg | 71.1±6.9 | 83.22±9.1 | 0.000 | 76.6±10.0 |
| Diabetes mellitus, n (%) | 77 (45.6) | 80 (55.9) | 0.068 | 157 (50.3) |
| Coronary heart disease, n (%) | 51 (30.2) | 44 (30.8) | 0.910 | 95 (30.4) |
| Body mass index, Kg/m | 25.8±3.5 | 25.9±3.5 | 0.771 | 25.9±3.4 |
| FBG, mmol/L | 6.0±2. 2 | 6.6±2.7 | 0.037 | 6.3±2.4 |
| HDL_C, mg/dL | 46.4±11.6 | 42.5±11.6 | 0.080 | 1.2±0.3 |
| LDL-C, mg/dL | 92.8±30.9 | 100.5±30.9 | 0.028 | 2.5±0.8 |
| Triglycerides, mg/dL | 150.6±106.3 | 186.1±159.5 | 0.049 | 1.9±1.5 |
| Smoking, n (%) | 62 (36.7) | 69 (48.3) | 0.039 | 131 (42.0) |
| Drinking, n (%) | 37 (21.9) | 48 (33.6) | 0.021 | 85 (27.2) |
| Uric acid, umol/L | 348.2±86.5 | 361.2±88.0 | 0.190 | 354.1±87.3 |
| Homocysteine, mmol/L | 14.6±7.0 | 15.3±8.4 | 0.410 | 14.9±7.6 |
| eGFR, mL/(min·1.73 m) | 87.1±17.2 | 89.9±17.9 | 0.164 | 88.4±17.5 |
| Hemoglobin, g/L | 135.8±16.1 | 137.2±16.4 | 0.469 | 136.5±16.2 |
| Heart rate, bpm | 68.9±10.2 | 68.4±11.1 | 0.642 | 68.6±10.7 |
| Antihypertensive agents, n (%) | 0.009 | |||
| ACEI/ARBs | 42 (29.4) | 62 (36.7) | 104 (33.3) | |
| CCBs | 31 (21.7) | 46 (27.2) | 77 (24.7) | |
| ACEI/ARBs+CCBs | 33 (23.1) | 42 (24.9) | 75 (24.0) | |
| Others | 37 (25.9) | 19 (11.2) | 56 (17.9) | |
| FBG – fasting blood-glucose; HDL-C – high density lipid-cholesterol; LDL-C – low density lipid-cholesterol; eGFR – estimated glomerular filtration rate; ACEI/ARBs – angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, CCBs calcium channel blockers. * Variables are presented as mean (SD) or n (%). ** We defined the following target BP values for antihypertensive therapy: | ||||